ArticleRegenerative therapy2025
Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunotherapy in Asia: current insights and prospects in Southeast Asia and Malaysia.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tisagenlecleucel, an autologous CD19-directed chimeric antigen receptor T-cell therapy, was approved in Japan, in March 2019 for patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukamia and r/r diffuse large B-cell lymphoma, and in August 2022 for patients with r/r follicular lymphoma. Post-approval, a key goal has been to upscale and continuously improve manufacturing and shipment success rates (MSR and SSR, respectively) in the commercial setting to meet the needs of patients worldwide, including in Japan. Herein, we report accrued experience from a 4-year journey of commercial tisagenlecleucel manufacturing process optimization for patients in Japan. Methods: Data were collected from the Novartis tisagenlecleucel manufacturing database, and only commercial tisagenlecleucel orders between August 2019 and July 2023 were included. The data for cancellations after shipment were based on cancellation forms obtained from institutions. Results: Since the first approval of tisagenlecleucel in Japan, its MSR and SSR improved over 4 years. Particularly, the MSR increased from 85.6 % in the first year to 95.3 % in the year 4, while the SSR increased from 92.4 % to 98.4 % in the same period. The corresponding termination and out-of-specification (OOS) rates decreased from 6.8 % to 0.9 %, and from 7.6 % to 3.7 %, respectively. The MSR (87.9 % versus 94.6 %), SSR (93.0 % versus 97.5 %), termination (6.0 % versus 1.9 %), overall OOS rates (6.1 % versus 3.5 %), and viability OOS (2.8 % versus 0.2 %) have improved significantly since the implementation of manufacturing process improvements in 2022. Conclusion: Continuous improvements in the tisagenlecleucel manufacturing process over the years resulted in higher manufacturing success and increased product availability for Japanese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.